Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

SIMPLE SUMMARY: Surrogate radiology-based endpoints such as progression-free survival (PFS) and objective response rate (ORR) are commonly used in oncology. However, their surrogacy with overall survival (OS) has not been evaluated in immunotherapy trials for hepatocellular carcinoma (HCC). We found...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabibbo, Giuseppe, Celsa, Ciro, Enea, Marco, Battaglia, Salvatore, Rizzo, Giacomo Emanuele Maria, Busacca, Anita, Matranga, Domenica, Attanasio, Massimo, Reig, Maria, Craxì, Antonio, Cammà, Calogero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796103/
https://www.ncbi.nlm.nih.gov/pubmed/33396833
http://dx.doi.org/10.3390/cancers13010090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796103/
https://www.ncbi.nlm.nih.gov/pubmed/33396833
http://dx.doi.org/10.3390/cancers13010090

Ejemplares similares